Laxxon Medical Corp., a global pioneer in the manufacturing and development of 3D screen-printed pharmaceuticals, has been granted a far-reaching US patent for the sequential release of multiple active ingredients in pharmaceutical dosage forms, thereby strengthening the company’s position in the pharmaceutical market. As announced today by the US-based company, the United States Patent and Trademark Office (USPTO) has issued US Patent 11,419,824 B2 for the controlled delivery of one or more pharmaceutical active ingredients within a drug delivery system via oral dosage forms.
The patent covers the sequential release of at least two pharmaceutical active ingredients (APIs) within a Drug Delivery System (DDS) developed and manufactured using 3D printing. Multi-drug medications and 3D printing are strongly emerging developments in the pharmaceutical industry. These new technologies are pushing the boundaries of medicine and defining the next generation of drugs.
Helmut Kerschbaumer, Chief Executive Officer of Laxxon, commented: “This patent represents a significant milestone in Laxxon’s development strategy and establishes Laxxon as a leading company in the 3D-printed drug market.”
Klaus Kühne, Chief Operations Officer of Laxxon, added: “More individualized and tailored medications are playing an increasingly important role in the future of drug manufacturing. This patent is a great success for Laxxon’s global IP strategy and will significantly improve our position in the highly competitive pharmaceutical market.”
Laxxon’s patent portfolio consists of more than 150 proprietary and in-licensed patents and patent applications, encompassing more than 3,000 patent claims. The portfolio includes patents and applications related to methods and devices for drug delivery systems.
ABOUT THE DDS (DRUG DELIVERY SYSTEM)
Laxxon’s Drug Delivery Systems (DDS) are oral, intra- or transdermal pharmaceutical application forms manufactured using 3D screen printing, which, due to the precise arrangement of active ingredients within the DDS, enables tailored administration and release profile of one or more active ingredients in a patient (human or animal).
Laxxon’s DDS optimize pharmacokinetics and pharmacodynamics, which can lead to improved clinical outcomes and, for example, fewer side effects, while requiring less active ingredients than conventional medications
ABOUT LAXXON MEDICAL
Laxxon Medical Corp. is a pharmaceutical technology company pioneering innovative pharmaceutical solutions with SPID® Technology (Screen Printing Innovational Drug Technology), an additive 3D screen printing process. Laxxon owns the worldwide exclusive rights to use and apply SPID® Technology for the development, manufacturing, and marketing of pharmaceutical dosage forms.
